Agenus (AGEN) Stock Rating Upgraded by BidaskClub
Agenus (NASDAQ:AGEN) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.
A number of other research firms also recently issued reports on AGEN. ValuEngine downgraded Agenus from a “sell” rating to a “strong sell” rating in a research note on Friday, December 29th. Zacks Investment Research upgraded Agenus from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research note on Wednesday, October 25th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Agenus presently has an average rating of “Hold” and an average price target of $5.81.
Shares of Agenus (AGEN) opened at $3.65 on Friday. The stock has a market capitalization of $312.41, a PE ratio of -3.12 and a beta of 2.10. Agenus has a 52 week low of $3.20 and a 52 week high of $5.45. The company has a debt-to-equity ratio of -2.39, a quick ratio of 1.55 and a current ratio of 1.55.
Several hedge funds have recently bought and sold shares of AGEN. Artal Group S.A. lifted its position in shares of Agenus by 25.0% during the 3rd quarter. Artal Group S.A. now owns 2,500,000 shares of the biotechnology company’s stock valued at $11,025,000 after buying an additional 500,000 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Agenus by 5.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,530,585 shares of the biotechnology company’s stock valued at $13,805,000 after buying an additional 174,162 shares in the last quarter. Virtus Fund Advisers LLC purchased a new position in Agenus in the 4th quarter worth approximately $320,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Agenus by 511.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 88,942 shares of the biotechnology company’s stock worth $392,000 after purchasing an additional 74,407 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its holdings in Agenus by 12.8% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 617,700 shares of the biotechnology company’s stock worth $2,724,000 after purchasing an additional 70,000 shares in the last quarter. 37.30% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Agenus (AGEN) Stock Rating Upgraded by BidaskClub” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/agenus-agen-stock-rating-upgraded-by-bidaskclub/1858439.html.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.